Tower Research Capital (TRC)’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-100
| Closed | -$221 | – | 6402 |
|
|
2023
Q2 | $221 | Buy |
+100
| New | +$207 | ﹤0.01% | 5731 |
|
|
2022
Q4 | – | Sell |
-3,768
| Closed | -$10K | – | 6638 |
|
|
2022
Q3 | $10K | Buy |
3,768
+2,443
| +184% | +$6.08K | ﹤0.01% | 4607 |
|
|
2022
Q2 | $3K | Sell |
1,325
-10,433
| -89% | -$22.8K | ﹤0.01% | 5454 |
|
|
2022
Q1 | $35K | Sell |
11,758
-857
| -7% | -$3.22K | ﹤0.01% | 3019 |
|
|
2021
Q4 | $56K | Sell |
12,615
-12,921
| -51% | -$61.3K | ﹤0.01% | 2689 |
|
|
2021
Q3 | $124K | Sell |
25,536
-6,227
| -20% | -$34.3K | ﹤0.01% | 2214 |
|
|
2021
Q2 | $217K | Buy |
31,763
+23,579
| +288% | +$191K | 0.01% | 1859 |
|
|
2021
Q1 | $58K | Sell |
8,184
-3,665
| -31% | -$26.4K | ﹤0.01% | 3000 |
|
|
2020
Q4 | $75K | Sell |
11,849
-33,018
| -74% | -$194K | ﹤0.01% | 2649 |
|
|
2020
Q3 | $243K | Buy |
44,867
+37,786
| +534% | +$187K | ﹤0.01% | 2390 |
|
|
2020
Q2 | $37K | Buy |
+7,081
| New | +$31.5K | ﹤0.01% | 3291 |
|
|
2019
Q3 | – | Sell |
-2,174
| Closed | -$9K | – | 4646 |
|
|
2019
Q2 | $9K | Buy |
2,174
+578
| +36% | +$2.75K | ﹤0.01% | 2641 |
|
|
2019
Q1 | $9K | Buy |
+1,596
| New | +$10.3K | ﹤0.01% | 2762 |
|
|
2018
Q3 | – | Sell |
-1,014
| Closed | -$11K | – | 4377 |
|
|
2018
Q2 | $11K | Sell |
1,014
-432
| -30% | -$4.89K | ﹤0.01% | 2754 |
|
|
2018
Q1 | $19K | Buy |
+1,446
| New | +$21.5K | ﹤0.01% | 2204 |
|
|
2017
Q4 | – | Sell |
-3,258
| Closed | -$82K | – | 4170 |
|
|
2017
Q3 | $82K | Buy |
3,258
+3,204
| +5,933% | +$74.6K | 0.01% | 1561 |
|
|
2017
Q2 | $1K | Sell |
54
-52
| -49% | -$1.15K | ﹤0.01% | 2537 |
|
|
2017
Q1 | $2K | Buy |
+106
| New | +$1.67K | ﹤0.01% | 2693 |
|
|
2016
Q4 | – | Sell |
-100
| Closed | -$1K | – | 4548 |
|
|
2016
Q3 | $1K | Sell |
100
-1,472
| -94% | -$19.5K | ﹤0.01% | 3413 |
|
|
2016
Q2 | $22K | Buy |
1,572
+1,111
| +241% | +$16.4K | ﹤0.01% | 2169 |
|
|
2016
Q1 | $7K | Buy |
461
+261
| +131% | +$3.99K | ﹤0.01% | 2425 |
|
|
2015
Q4 | $4K | Sell |
200
-1,361
| -87% | -$26K | ﹤0.01% | 3285 |
|
|
2015
Q3 | $30K | Buy |
+1,561
| New | +$38.9K | ﹤0.01% | 1404 |
|
|
2015
Q1 | – | Sell |
-227
| Closed | -$9K | – | 5073 |
|
|
2014
Q4 | $9K | Sell |
227
-446
| -66% | -$10.6K | ﹤0.01% | 2267 |
|
|
2014
Q3 | $16K | Buy |
673
+588
| +692% | +$15.3K | ﹤0.01% | 2498 |
|
|
2014
Q2 | $2K | Sell |
85
-29
| -25% | -$946 | ﹤0.01% | 3486 |
|
|
2014
Q1 | $4K | Sell |
114
-33
| -22% | -$1.3K | ﹤0.01% | 3489 |
|
|
2013
Q4 | $6K | Sell |
147
-137
| -48% | -$5.82K | ﹤0.01% | 3439 |
|
|
2013
Q3 | $11K | Sell |
284
-199
| -41% | -$7.13K | ﹤0.01% | 3163 |
|
|
2013
Q2 | $18K | Buy |
+483
| New | +$20.7K | ﹤0.01% | 1832 |
|
Tower Research Capital (TRC)'s PRTK Position: Q3 2023 in Review
Tower Research Capital (TRC) sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 100 shares — an estimated $221 sold.
Tower Research Capital (TRC) first reported a position in PRTK in Q2 2013 and held it in 30 quarters. The position peaked at $243K in Q3 2020. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Tower Research Capital (TRC) reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 100 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $221.
- Tower Research Capital (TRC) first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- Tower Research Capital (TRC)'s Paratek Pharmaceuticals, Inc. position peaked at $243K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.